

ONLINE RESOURCE 2

Article title

Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [¹⁸F]FDG in gynaecological malignancies: systematic literature review and meta-analysis

Journal

European Journal of Nuclear Medicine and Molecular Imaging

Authors

Anita Florit, MD, Elizabeth J. De Koster, MD, Serena Sassano, MD, Lejla Alic, PhD, Giusi Pisano, MD, Floris H.P. van Velden, PhD, Salvatore Annunziata, MD, PhD, Irina Primac, PhD, Maria Rosaria Ruggiero, PhD, Cristina Müller, PhD, Evis Sala, MD, PhD, Wolfgang P. Fendler, MD, PhD, Giovanni Scambia, MD, Lioe-Fee de Geus-Oei, MD, PhD, Anna Fagotti, MD, PhD, Vittoria Rufini, MD, Angela Collarino, MD, PhD


Corresponding author

Prof. Vittoria Rufini


UOC Medicina Nucleare, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Largo A. Gemelli, 8, 00168 Rome, Italy

E-mail: vittoria.rufini@unicatt.it


Supplementary Fig. 3 Per-lesion analysis of the primary tumor in ovarian cancer. (A) ⁶⁸Ga-FAPI sensitivity; (B) [¹⁸F]FDG sensitivity; (C) ⁶⁸Ga-FAPI specificity; (D) [¹⁸F]FDG specificity; (E) ⁶⁸Ga-FAPI positive predictive value (PPV); (B) [¹⁸F]FDG PPV; (C) ⁶⁸Ga-FAPI negative predictive value (NPV); (D) [¹⁸F]FDG NPV




E



F



G



H

